Clinical Trial Search

Primary: Time From Baseline to First Multiple Sclerosis Relapse (in Weeks) — 35.5; 40.9 weeks — p=0.1384

Primary: Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate — 0.501; 0.389; 0.319 relapses per year — p=0.0001

Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale

Primary: Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16 — 0.9; 3.0 lesions — p=<0.001

Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…

Primary: Annualized Relapse Rate (ARR) — 0.091; 0.178 relapses per participant-years — p=0.0022

Primary: Safety and Tolerability — 10; 9; 10; 9 Participants with at least one TEAE

Primary: Relapses Post Partum — 2; 7 Participants

Primary: Number of Participants Developing a New MS Relapse and/or MRI Brain Lesion Over the Course of the Study Duration — 6; 16 Participants — p=0.521

Primary: ARMS (Assessing Relapses in Multiple Sclerosis) ADL Scores (Activities of Daily Living) — 3.1; 4.9 score on a scale — p=0.003

Primary: Total Number of Gd-Enhancing T1-Weighted MRI Lesions Per Scan Averaged During Weeks 12, 16, 20, and 24 — 1.819; 0.710; 1.237; 1.477 lesions per scan

Primary: The Number of New or Recurrent Gd-enhancing Lesions That Appear on Brain T1-weighted MRI — 0.12 lesions

Primary: Change From Baseline in Patient-reported Treatment Satisfaction — 19.57; 5.83 score on a scale

Primary: Annualized Relapse Rate [ARR]: Poisson Regression Estimates — 0.539; 0.370; 0.369 relapses per year — p=0.0005

Primary: Number of Days Until First On-study Relapse — NA; 103 days — p=0.125

Primary: Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening…

Primary: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks — 0.292; 0.156 relapses/participant year of treatment — p=<0.0001

Primary: Safety and Tolerability — 21; 22 participants

Primary: Annualized Relapse Rate (ARR) — 0.076; 0.188 relapses per participant-years — p=<0.0001

Primary: Time Course to Return of Radiological and/or Clinical Evidence of Multiple Sclerosis Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance…

Primary: Number of Participants Experiencing Adverse Events (AEs) — 668; 775; 776 Participants

Primary: Annualized Relapse Rate (ARR) at 1 Year — 0.397; 0.288; 0.256 relapses per person-years — p=0.0114

Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants

Primary: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks In Double Blind Period — 0.290; 0.155 relapses/participant year of…

Primary: MRI Parameter- Percent Brain Volume Change for 2 Years — -0.862; -0.49 percent change per year

Primary: Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio…

Primary: Mean Overall Response Score (ORS) at Week 52 — 0.04; -0.17; -0.17 score on a scale

Primary: Placebo-Controlled Phase: Time to Confirmed Disease Progression (CDP) Confirmed After At Least 3 Months (Number of Participants With CDP After At Least 3 Months) — 73…

Primary: Percentage of Relapse-free RMS Subjects — 66.3 percentage of subjects

Primary: Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005) — 310; 182; 97 days — p=<0.001